Claims for Patent: 7,790,704

Summary for Patent: 7,790,704

Title:	Thrombopoietin mimetics
Abstract:	Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Inventor(s):	Duffy; Kevin J. (Collegeville, PA), Erickson-Miller; Connie (King Of Prussia, PA), Jenkins; Julian (Collegeville, PA), Luengo; Juan I. (Collegeville, PA)
Assignee:	GlaxoSmithKline, LLC (Philadelphia, PA)
Application Number:	12/141,397
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,790,704
Patent Claims:	1. A method for enhancing platelet production in a human in need thereof which comprises administering to such human a therapeutically effective amount of a compound of the following formula: ##STR00014## wherein Q is --COOH; or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 wherein the compound is administered orally. 3. The method of claim 1 wherein the compound is administered parenterally. 4. The method of claim 1 further comprising co-administering a therapeutically effective amount of an agent selected from the group consisting of: a colony stimulating factor, cytokine, chemokine and an interleukin or cytokine receptor agonist or antagonist. 5. The method of claim 4 wherein the agent is selected from the group consisting of: G-CSF, GM-CSF, TPO, M-CSF, EPO, Gro-beta, IL-11, SCF, FLT3 ligand, LIE, IL-3, IL-6, IL-1, NESP, SD-01, IL-8 and IL-5. 6. A method for enhancing platelet production obtained from a human donor which comprises administering to such donor a therapeutically effective amount of the compound 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid or a pharmaceutically acceptable salt thereof; prior to platelet pheresis, blood donation or platelet donation. 7. The method of claim 6 wherein the compound is administered orally. 8. The method of claim 6 wherein the compound is administered parenterally. 9. The method of claim 6 further comprising co-administering a therapeutically effective amount of an agent selected from the group consisting of: a colony stimulating factor, cytokine, chemokine and an interleukin or cytokine receptor agonist or antagonist. 10. The method of claim 9 wherein the agent is selected from the group consisting of: G-CSF, GM-CSF, TPO, M-CSF, EPO, Gro-beta, IL-11, SOF, FLT3 ligand, LIE, IL-3, IL-6, IL-1, NESP, SD-01, IL-8 and IL-5.